Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

453 results
Display

Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma

Na JC, Kim JH, Kim SY, Gu YR, Jun DY, Lee HH, Yoon YE, Choi KH, Hong SJ, Han WK

PURPOSE: Renal cell carcinoma is a heterogeneous kidney cancer, and over 403,000 cases were reported worldwide in 2018. Current methods for studying renal cell carcinoma are limited to two-dimensional (2D)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study

Kim SH, Lee DE, Joung JY, Seo HK, Lee KH, Chung J

PURPOSE: This study aimed to compare progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) in Heng intermediate-risk patients with metastatic renal cell carcinoma (mRCC) treated with first-line immunotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of perioperative blood transfusion on oncologic outcomes in patients with nonmetastatic renal cell carcinoma treated with curative nephrectomy: A retrospective analysis of a large, single-institutional cohort

Seon DY, Kwak C, Kim HH, Ku JH, Kim HS

PURPOSE: To evaluate the impact of perioperative blood transfusion (PBT) on oncologic outcomes after surgery in patients with nonmetastatic renal cell carcinoma (RCC). MATERIALS AND METHODS: This retrospective review included 2,329...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion

Woo CG, Yun SJ, Son SM, Lim YH, Lee OJ

The World Health Organization 2016 edition assigned anaplastic lymphoma kinase (ALK) rearrangement-associated renal cell carcinoma (ALK-RCC) as an emerging renal tumor entity. Identifying ALK-RCC is important because ALK inhibitors have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma

Choi SW, Lee JM, Kim DG, Noh MH

A 64-year-old man was treated with sunitinib as a first-line therapy for metastatic renal cell carcinoma. He was given oral sunitinib in cycles of 50 mg once daily for 2...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma

Hwang HS, Park YY, Shin SJ, Go H, Park JM, Yoon SY, Lee JL, Cho YM

BACKGROUND: Mechanism and predictive biomarkers for tyrosine kinase inhibitor (TKI) resistance of advanced clear cell renal cell carcinoma (ccRCC) have not been fully evaluated. METHODS: We performed gene expression profiling on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Significance of Systemic Inflammatory Response in Patients with Synchronous and Metachronous Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors

Choi J, Kim TJ, Sung HH, Jeon HG, Jeong BC, Jeon SS, Lee HM, Choi HY, Kang M, Seo SI

PURPOSE: To determine whether systemic inflammatory response (SIR), particularly platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR), has different prognostic role between patients with metastatic renal cell carcinoma (mRCC) receiving first-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical features and outcomes in kidney transplant recipients with renal cell carcinoma: a single-center study

Park KH, Yoon JA, Kim HS, Kim H, Park SK, Kim YH, Hong B, You D, Jeong IG, Baek CH

BACKGROUND: Previous studies have recommended a 2- to 5-year waiting time prior to kidney transplantation (KT) in patients with end-stage renal disease (ESRD) and symptomatic renal cell carcinoma (RCC) and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cutaneous metastatic renal cell carcinoma to the scalp

Yang HJ, Kang SY

Renal cell carcinoma (RCC) represents 2% to 3% of human cancers and is aggressive, with metastatic capability. The frequent metastatic sites are lung, bone, and liver. Reports of RCC metastatic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker

Kim KH, Lee HH, Yoon YE, Na JC, Kim KS, Han WK

PURPOSE: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC). MATERIALS AND METHODS: Between...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Neutrophil-to-Lymphocyte Ratio Predicts Pathological Renal Sinus Fat Invasion in Renal Cell Carcinomas of ≤7 cm with Presumed Renal Sinus Fat Invasion

Kim J, Park JS, Heo JE, Elghiaty A, Jang WS, Rha KH, Choi YD, Ham WS

PURPOSE: Computed tomography (CT) is the most useful diagnostic modality for staging renal cell carcinoma (RCC). However, CT is limited in its ability to predict renal sinus fat invasion (SFI)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Two-DNA Methylation Signature to Improve Prognosis Prediction of Clear Cell Renal Cell Carcinoma

Shi S, Ye S, Wu X, Xu M, Zhuo R, Liao Q, Xi Y

PURPOSE: Effective biomarkers and models are needed to improve the prognostic prospects of clear cell renal cell carcinoma (ccRCC). The purpose of this work was to identify DNA methylation biomarkers...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi JG, Seo JY, Park I, Lee JL

PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early Experiences with Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Failed Target Therapy

Lee JH, Kang M, Chung JH, Sung HH, Jeon HG, Jeong BC, Jeon SS, Lee HM, Park SH, Kim B, Kwon GY, Seo SI

PURPOSE: The efficacy of nivolumab in metastatic renal cell carcinoma (mRCC) has been proven. However, the nivolumab experience in Korean patients with mRCC is still poorly reported. We report initial...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The pancreas as a target of metastasis from renal cell carcinoma: Results of surgical treatment in a single institution

Glinka J, Sanchez Claria R, Ardiles V, de Santibañes E, Pekolj J, de Santibañes M, Mazza O

BACKGROUNDS/AIMS: Metastasis in the pancreatic gland is infrequent, representing between 2–5% of the tumors that affect this organ. However, secondary lesions of clear cell renal carcinoma (CCRC) can occur mainly...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter to the editor: Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma

Joob B, Wiwaniitkit V

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma

Kang HW, Park H, Seo SP, Byun YJ, Piao XM, Kim SM, Kim WT, Yun SJ, Jang W, Shon HS, Ryu KH, Lee SC, Kim WJ, Kim YJ

BACKGROUND: Little is known about epigenetic silencing of genes by promoter hypermethylation in renal cell carcinoma (RCC). The aim of this study was to identify prognostic methylation markers in surgically...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change

Kim SH, Park WS, Chung J

PURPOSE: Multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) and clear cell renal cell carcinoma with cystic change (MCRCC) have different prognoses despite similar histologic characteristics. The aim of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry

Kim JK, Kim SH, Song MK, Joo J, Seo SI, Kwak C, Jeong CW, Song C, Hwang EC, Seo IY, Lee H, Hong SH, Park JY, Chung J, Korean Renal Cell Carcinoma Study Group

PURPOSE: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Potential Oncogenic Role of the Papillary Renal Cell Carcinoma Gene in Non-Small Cell Lung Cancers

Jang SH, Jiang Y, Shin S, Jung SH, Jung CK, Chung YJ

PURPOSE: Papillary renal cell carcinoma (PRCC) gene, which located in 1q23.1, is recurrently amplified in non-small cell lung cancer (NSCLC). However, it is unknown whether PRCC is overexpressed in primary...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr